SecBot SecBot
8-K ·Filed Aug 5, 2026

ZBH

ZIMMER BIOMET HOLDINGS, INC.
BULLISH
Impact 6/10
Horizondays Processed3mo ago SEC0001193125-26-333761
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The guidance raise and beat confirm underlying demand momentum in hips and the Technology & Data segment. However, with 22 Hold ratings and a prior neutral reaction to a similar beat, the upside may be capped. Monitor the earnings call for details on the ROSA Shoulder System launch and the go-to-market transformation timeline.

DirectionBullish
Confidencehigh
Horizondays

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$98.16
T+0 close · Aug 5, 2026 · via day close
Latest settled
−1.02%
T+60 · $97.16
Vs SPY
−1.22%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 5 $98.16entry
  2. T+1 · 3mo ago −0.99%α −0.83% · $97.19
  3. T+5 · 3mo ago −0.28%α −0.63% · $97.89
  4. T+20 · 3mo ago +1.37%α +1.97% · $99.50
  5. T+60 · 19d ago −1.02%α −1.22% · $97.16
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Zimmer Biomet reported Q2 2026 adjusted EPS of $2.07, a 3.0% beat vs. consensus of $2.01, on revenue of $2.177B (above $2.14B consensus). Revenue grew 4.8% reported (4.0% organic constant currency). The company raised full-year 2026 guidance: reported revenue growth to 3.9%-4.9% (from 2.5%-4.5%) and adjusted EPS to $8.47-$8.59 (from $8.40-$8.55), signaling confidence in H2 momentum. The beat and guidance raise are positive, but the magnitude is modest for a large-cap medtech, and the prior quarter's cross-filing context showed a similar beat with a neutral market reaction, suggesting limited upside surprise.

Key Financial Metrics

EPS
$2.07
est $2.01 · +3.0%
Revenue
$2.2B
est $2.1B · +1.7% · +4.8% YoY
Rating
beat
Guidance
3.9% - 4.9% reported revenue change
raised
Free Cash Flow
$308.3M
Gross Margin
63.3%

Key Facts

  • Q2 2026 net sales of $2.177B, up 4.8% reported and 4.0% organic constant currency YoY
  • Adjusted diluted EPS of $2.07, beating consensus of $2.01 by 3.0%
  • Full-year 2026 guidance raised: reported revenue growth to 3.9%-4.9% (from 2.5%-4.5%), adjusted EPS to $8.47-$8.59 (from $8.40-$8.55)
  • Operating cash flow of $447.9M and free cash flow of $308.3M in Q2
  • Share repurchase expectations increased to up to $1 billion for FY 2026

Financial Impact

Q2 revenue $2.177B vs $2.14B consensus; adjusted EPS $2.07 vs $2.01 consensus; FY guidance raised by ~$0.10 at midpoint

revenueepsguidancecash flow

Risk Factors

  • Knee segment growth decelerated to 0.4% reported (0.1% constant currency), signaling competitive or market share pressure
  • Restructuring charges of $29.8M and litigation charges of $12.3M weighed on GAAP results
  • Net debt increased to $7.069B from $6.927B at year-end, partly due to $500.8M in share repurchases

Market Snapshot

Exchange
NYSE
Sector
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Analyst Consensus
33% bullish (33 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-333761
Document: zbh-20260805.htm0001193125-26-333761
Document: 0001193125-26-333761-index-headers.html0001193125-26-333761
Document: 0001193125-26-333761-index.html0001193125-26-333761
Document: 0001193125-26-333761.txt0001193125-26-333761
8-K Data (Synthetic)0001193125-26-333761

Track record

17 reports on ZBH

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +8.74% at T+60 after the Apr 28, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 3/10 Entry $103.21 Now $101.41 −1.74% settles Nov 20
  2. Nov 9, 20267d ago 424B5 Neutral 3/10 Entry $107.32 Now $101.41 −5.51% settles Nov 17
  3. Nov 9, 20267d ago 424B5 Neutral 3/10 Entry $107.32 Now $101.41 −5.51% settles Nov 17
  4. Nov 5, 202611d ago 424B5 Neutral 3/10 Entry $106.85 to $104.56 Now $101.41 −5.09% ▼ −2.14% −5.43% vs SPY
  5. Nov 5, 202611d ago 424B5 Neutral 2/10 Entry $106.85 to $104.56 Now $101.41 −5.09% ▼ −2.14% −5.43% vs SPY
  6. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $110.15 to $107.47 Now $101.41 −7.93% ▼ −2.43% −1.52% vs SPY
  7. Oct 26, 202621d ago Institutional Cluster Bearish 4/10 Entry $97.44 to $94.52 Now $101.41 −4.07% ▲ +3.00% +1.74% vs SPY
  8. Oct 21, 202627d ago Court Ruling Bearish 6/10 Entry $98.81 to $97.47 Now $101.41 −2.63% ▲ +1.36% +2.06% vs SPY
  9. Sep 15, 20268w ago Insider Cluster Neutral 3/10 Entry $96.53 to $90.64 Now $101.41 +5.06% ▼ −6.10% −8.17% vs SPY
  10. Sep 2, 202610w ago Court Ruling Neutral 2/10 Entry $98.66 to $93.24 Now $101.41 +2.79% ▼ −5.49% −4.34% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens in 7h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 5, 2026